Covered recipient · General Payments record
STEPHANIE N WUEST
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2024
$265.34
- Reported across 15 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $265.34 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $71.01 | 4 |
| Teva Pharmaceuticals USA, Inc. | $44.93 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $30.59 | 2 |
| ABBVIE INC. | $19.86 | 1 |
| Amgen Inc. | $18.69 | 1 |
| Merck Sharp & Dohme Corporation | $18.66 | 1 |
| Lundbeck LLC | $18.55 | 1 |
| Organon LLC | $16.40 | 1 |
| Lilly USA, LLC | $13.49 | 1 |
| Novo Nordisk AS | $13.16 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $265.34 | 15 |
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.86 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106365287 | CMS |
| Amgen Inc. | $18.69 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117722406 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.08 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118240530 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.51 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118240532 | CMS |
| Lilly USA, LLC | $13.49 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135350014 | CMS |
| Lundbeck LLC | $18.55 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145982777 | CMS |
| Merck Sharp & Dohme LLC | $18.66 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141871035 | CMS |
| Novo Nordisk Inc | $13.16 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096923160 | CMS |
| Organon Llc | $16.40 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136262347 | CMS |
| PFIZER INC. | $17.18 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131495085 | CMS |
| PFIZER INC. | $21.18 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131459388 | CMS |
| PFIZER INC. | $17.87 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131528672 | CMS |
| PFIZER INC. | $14.78 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131560997 | CMS |
| Teva Pharmaceuticals USA, Inc. | $25.44 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151566071 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.49 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151566115 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.